Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 08 August 2012 | By Alexander Gaffney, RAC
The European Medicines Agency (EMA) has released a new guideline on clinical trials conducted to assess chronic obstructive pulmonary disease (COPD) products, updating an existing guideline regulators said had grown outdated.
Released 8 August, Guideline on clinical investigation of medical products in the treatment of chronic obstructive pulmonary disease is scheduled to come into effect on 1 September 2012 after more than two years in development. EMA officials said the guideline would replace a Points to Consider (PtC) document released in May 1999 of the same name.
EMA officials write the guideline builds upon the PtC document to reflect new scientific discoveries related to COPD, an irreversible narrowing of the airways leading to the lungs, and advances in clinical practice guidelines.
The new guidelines state sponsors should aim to assess COPD products in homogenous groups of patients with, "Mainly irreversible airway function, which would allow for better characterization of the effect of the drug."
"However it is accepted that up to 50% of patients with COPD do have some degree of reversibility of airflow obstruction and therefore some degree of freedom in respect of the inclusion of patients with differing degrees of airway reversibility, and the resultant need for sub-group analyses in respect of these differing degrees of airway reversibility, will be required," explained EMA. "Consistency of effect across such subgroups should be demonstrated."
If patients with a degree of reversibility are included, sponsors will need to show the effects of the drug would be applicable to those with irreversible declines in lung function as well, and that the impact of the drug was, "Not driven by this subset of patients."
The severity of the target population should be defined before the start of the trial using measures of "airflow limitation, symptoms, risk of exacerbation and presence of co-morbidities." EMA wrote.
All physical patient characteristics, including objective measures of the state of their COPD, should be recorded before the start of the trial. Other factors, including the patient's history of smoking or the patient's inclusion in a relevant sub-population, should be identified and recorded, officials said.
The guideline notes that different drugs developed for COPD will be aimed at different methods of combating the disease and should be assessed accordingly.
"Depending on the mechanism of action of the drug substance under evaluation, a complete characterization of the effect of any therapy in COPD would require the inclusion of a number of different variables belonging to those domains expected to be affected by the study drug, because most treatments will produce benefits in more than one area," explained EMA.
Those endpoints will include lung function, exacerbations and the severity of COPD, patient- and physician-reported outcomes, exercise capacity, composite scores based on airway obstruction, need for rescue medication, assessments by imaging and other endpoints such as biomarkers and physical activity.
European regulators also explained confirmatory trials using a comparator as a source of comparison were, "Difficult, as drugs with different modes of action and combinations of treatments are used in the management and treatment of COPD." Officials recommended the use of either a placebo and a comparator or just a comparator, though they were unlikely to accept the results of a trial using only a placebo as a comparison.
"The choice of the comparator will depend also on the severity of COPD and the type of study design," EMA explains in the guideline. "Ultimately, in the selection of the comparator, consideration must be given to current clinical treatment recommendations."
Regulators also cited their safety concerns regarding the drug class, noting the drugs are difficult to stop using once symptoms have been successfully managed. "Therefore a complete safety evaluation, as the primary safety assessment, is required for any treatment for COPD and required focus on the occurrence of adverse events for each individual component and adverse events known to occur with the particular combination of active drugs," wrote EMA in the guideline.
At least one year of safety data is required, with additional data preferred.
Tags: Lungs, COPD, Latest News, guideline, drug
Regulatory Focus newsletters
All the biggest regulatory news and happenings.